



## Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder



Anna-Martha V. Fontanari<sup>a,b</sup>, Tahiana Andreatza<sup>a</sup>, Ângelo B. Costa<sup>a</sup>, Jaqueline Salvador<sup>a</sup>, Walter J. Koff<sup>a</sup>, Bianca Aguiar<sup>b,c</sup>, Pamela Ferrari<sup>b</sup>, Raffael Massuda<sup>b</sup>, Mariana Pedrini<sup>b</sup>, Esalba Silveira<sup>a</sup>, Paulo S. Belmonte-de-Abreu<sup>b</sup>, Clarissa S. Gama<sup>a</sup>, Marcia Kauer-Sant'Anna<sup>b</sup>, Flavio Kapczinski<sup>b</sup>, Maria Ines R. Lobato<sup>a,b,\*</sup>

<sup>a</sup> Gender Identity Disorder Program, Hospital de Clinicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

<sup>b</sup> Laboratory of Molecular Psychiatry, INCT for Translational Medicine, Hospital de Clinicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

<sup>c</sup> Postgraduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

### ARTICLE INFO

#### Article history:

Received 13 November 2012

Received in revised form

18 April 2013

Accepted 19 April 2013

#### Keywords:

Gender identity disorder

Brain-derived neurotrophic factor

Transsexualism

### ABSTRACT

Gender Identity Disorder (GID) is characterized by a strong and persistent cross-gender identification that affects different aspects of behavior. Brain-derived neurotrophic factor (BDNF) plays a critical role in neurodevelopment and neuroplasticity. Altered BDNF-signaling is thought to contribute to the pathogenesis of psychiatric disorders and is related to traumatic life events. To examine serum BDNF levels, we compared one group of DSM-IV GID patients ( $n = 45$ ) and one healthy control group ( $n = 66$ ). Serum BDNF levels were significantly decreased in GID patients ( $p = 0.013$ ). This data support the hypothesis that the reduction found in serum BDNF levels in GID patients may be related to the psychological abuse that transsexuals are exposed during their life.

© 2013 Elsevier Ltd. All rights reserved.

### 1. Introduction

Gender Identity Disorder (GID) is characterized by a strong and persistent cross-gender identification that affects different aspects of behavior (WHO, 1992; APA, 2000). The individuals experience gender dysphoria and desire to live and be accepted as a member of the opposite sex (Dhejne et al., 2011). It is a highly disabling disorder, characterized by intense psychological suffering (Lobato et al., 2006). The recommended treatment may be provided by a multidisciplinary team with physical and psychological assistance, hormone therapy and sex reassignment surgery (Lobato et al., 2006; Salvador et al., 2012). GID is a rare condition, with an estimated worldwide lifetime prevalence ranging 0.001–0.002% (Hoshiai et al., 2010).

The pathophysiology and etiopathogenesis of GID have not been fully elucidated (Selvaggi and Bellringer, 2011). Most of the current hypotheses on the possible cause of transsexuality presume a combination of a genetic background and an early organizational effect on the interaction of sex hormones with the developing brain

during critical fetal periods (Garcia-Falgueras and Swaab, 2008). Results from a Dutch research group have showed a neurological basis for gender identity with sexual morphological differentiation of the brain (Garcia-Falgueras and Swaab, 2008; Kruijver et al., 2000; Selvaggi and Bellringer, 2011; Swaab et al., 2002; Zhou et al., 1995).

Lifetime psychiatric comorbidity in GID patients is high, and this should be taken into account in their assessment and treatment planning (Hoshiai et al., 2010). For most GID patients, a strong and persistent identification with the opposite sex and discomfort with one's own sex is a life challenge that often creates distress and carries potential stigmatization (Hoshiai et al., 2010; Matsumoto et al., 2009). Moreover, it was reported that children with GID are at high risk for developing psychiatric problems (Wallien, 2007). Kersting et al. (2003) found a high prevalence of childhood trauma, especially emotional abuse and emotional neglect, in the transsexual sample (Kersting et al., 2003).

Brain-derived neurotrophic factor (BDNF) is a member of the growth factor family, involved in synaptic plasticity, neurogenesis, neuronal survival and normal maturation of neuronal developmental pathways (Fernandes et al., 2009; Gama et al., 2007; Grande et al., 2010). BDNF has a widely reported relation with corticosteroids that appear to play a key role in the environmentally

\* Corresponding author.

E-mail address: [mirlobato@gmail.com](mailto:mirlobato@gmail.com) (M.I.R. Lobato).

mediated vulnerability to psychopathology (Grande et al., 2010). Besides, BDNF serum levels have been associated with traumatic life events and psychiatric disorders (Boulle et al., 2012; Kauer-Sant'Anna et al., 2007).

Given the evidence that GID patients suffer from chronic stress (Kersting et al., 2003; Matsumoto et al., 2009) and that chronic stress and psychiatric disorders are related to a decrease on BDNF levels (Kauer-Sant'Anna et al., 2007), we compared serum BDNF levels in a group of GID patients and a group of healthy controls. The aim of the present study, therefore, was to evaluate whether GID patients have lower BDNF levels than controls.

## 2. Methods

This study protocol was approved by the Ethical Committee of the Hospital de Clínicas de Porto Alegre, Brazil (HCPA). All subjects were advised about the procedure and signed the informed consent prior to participate in the study. Forty-five GID outpatients from the HCPA Programa de Transtorno de Identidade de Gênero (PROTIG) and sixty-six healthy controls were enrolled in this study protocol. The group of patients had to fulfill Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) criteria for GID. All patients were under hormone-therapy, using the standard treatment for GID patients. Exclusion criteria were the presence of any comorbid disorder (Axis I and/or Axis II) psychiatric disorder assessed by The Mini International Neuropsychiatric Interview 6.0 (MINI 6.0) (Sheehan et al., 1998) by a trained psychologist. HIV infection, physical intersex conditions, addiction to psychoactive substances, and age below 18 years old were also excluded. Any GID patients currently taking psychotropic medications were also excluded. The control group consisted of medication-free healthy volunteers who had no current, past history or first-degree family history of a major psychiatric disorder, dementia or mental retardation. Subjects and controls were matched for age and belonged to masculine sex.

Five milliliters of blood were withdrawn from each subject by venipuncture into a free-anticoagulant vacuum tube. The samples were centrifuged at 2000g during 10 min and serum was kept frozen at  $-80^{\circ}\text{C}$  until assayed. BDNF serum levels were measured with sandwich-ELISA, using a commercial kit according to the manufacturer's instructions (Milipore, USA). Briefly, microtiter plates (96-well flat-bottom) were coated for 24 h at  $4^{\circ}\text{C}$  with the samples diluted 1:75 in sample diluents and standard curve ranged from 7.8 to 500 pg/ml of BDNF. Plates were then washed four times with wash buffer, added biotinylated mouse anti-human BDNF monoclonal antibody (diluted 1:1000 with sample diluents), and incubated for 3 h at room temperature. After washing, a second incubation with streptavidin–horseradish peroxidase conjugate solution (diluted 1:1000) for 1 h at room temperature was carried out. After addition of substrate and stop solution, the amount of BDNF was determined (absorbance set in 450 nm). The standard curve demonstrates a direct relationship between optical density (OD) and BDNF concentration.

Analysis was performed using Statistical Product and Service Solutions 18.0 Version (SPSS). Mann–Whitney test was used to compare ages. Independent sample *t*-test was conducted to compare BDNF measures. Data were presented as mean  $\pm$  Standard Deviation (S.D.), and *p*-values  $<0.05$  were considered significant.

## 3. Results

Demographic characteristics were listed in Table 1. Serum BDNF levels were significantly lower ( $p = 0.013$ ) in GID patients (mean  $\pm$  S.D.:  $17.77 \text{ ng/mL} \pm 5.68$ ) when compared to controls

**Table 1**

Characteristics of healthy controls and individuals with GID.

	Individuals with GID ( $n = 45$ )	Controls ( $n = 66$ )
Gender (male/female)	100% Male-to-female	100% Male
Age <sup>a</sup>	31.55 (7.7)	30.92 (9.28)
Years of education <sup>a</sup>	10.20 (3.08)	11.42 (3.35)
BDNF <sup>a,b</sup>	17.77 (5.68)	20.76 (6.40)

<sup>a</sup> Mean (S.D.).

<sup>b</sup>  $p = 0.013$ .

( $20.77 \text{ ng/mL} \pm 6.41$ ; Fig. 1). The findings were not interfered by years of education.


## 4. Discussion

As far as we know, this is the first study to examine BDNF levels in GID patients. The findings of this study support our hypothesis that BDNF levels are decreased in GID patients comparing to controls.

According to previous studies, lower levels of BDNF were reported in many psychiatric disorders (Begliomini et al., 2007). Moreover, decreased serum BDNF levels were associated with childhood traumatic events in patients with bipolar disorder (Kauer-Sant'Anna et al., 2007). Kapczynsky et al. (2008) reported that factors that negatively influence the course of BD, such as life stress and trauma have been shown to be associated with a decrease in BDNF serum levels.

Early life events may have long-term effects on adult health and well being, in the form of repeated activation of stress responsive to biological mediators such as glucocorticoids and catechol amines (McEwen, 1998; McEwen and Stellar, 1993). Preclinical studies found that BDNF expression is regulated by stress responsive corticosteroids (Smith et al., 1995). A recent pre-clinical study found that exposure to adverse events early in life might increase the susceptibility to the adverse effects during adulthood (de Lima et al., 2011).

Few clinical studies have investigated the impact of traumatic childhood experiences on sexual identity and GID. Recent studies reported that children with GID are at high risk for developing psychiatric problems in childhood and that the lifetime psychiatric comorbidity in GID patients is high (Matsumoto et al., 2009; Wallien, 2007). Kersting et al. (2003) found a high prevalence of childhood trauma, especially emotional abuse and emotional neglect, in the transsexual sample (Kersting et al., 2003). GID patients are a group affected by stigma and discrimination (Infante et al., 2009; Meyer, 1995, 2003). Stigma, prejudice, and discrimination create a hostile and stressful social environment that causes mental health problems (Meyer, 2003). The concept of social stress



**Fig. 1.** Levels of serum BDNF in patients with GID and healthy controls.

متن کامل مقاله

دریافت فوری ←

**ISI**Articles

مرجع مقالات تخصصی ایران

- ✓ امکان دانلود نسخه تمام متن مقالات انگلیسی
- ✓ امکان دانلود نسخه ترجمه شده مقالات
- ✓ پذیرش سفارش ترجمه تخصصی
- ✓ امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
- ✓ امکان دانلود رایگان ۲ صفحه اول هر مقاله
- ✓ امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
- ✓ دانلود فوری مقاله پس از پرداخت آنلاین
- ✓ پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات